Last reviewed · How we verify
desferrioxamine
desferrioxamine is a Small molecule drug developed by Brigham and Women's Hospital. It is currently in Phase 3 development for Chronic Iron Overload, Poisoning by iron AND/OR its compounds. Also known as: Desferal, desferoxamine.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | desferrioxamine |
|---|---|
| Also known as | Desferal, desferoxamine |
| Sponsor | Brigham and Women's Hospital |
| Target | Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
- Chronic Iron Overload
- Poisoning by iron AND/OR its compounds
Common side effects
Key clinical trials
- Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors (PHASE1)
- Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) (PHASE1)
- Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) (PHASE2)
- Early Screening and Treatment of Heart Complication in Sickle Cell Disease (PHASE2)
- Synergistic Minimally Invasive Surgery and Deferoxamine in ICH (PHASE2, PHASE3)
- The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL (PHASE3)
- Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) (EARLY_PHASE1)
- 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- desferrioxamine CI brief — competitive landscape report
- desferrioxamine updates RSS · CI watch RSS
- Brigham and Women's Hospital portfolio CI
Frequently asked questions about desferrioxamine
What is desferrioxamine?
What is desferrioxamine used for?
Who makes desferrioxamine?
Is desferrioxamine also known as anything else?
What development phase is desferrioxamine in?
What does desferrioxamine target?
Related
- Target: All drugs targeting Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha
- Manufacturer: Brigham and Women's Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Chronic Iron Overload
- Indication: Drugs for Poisoning by iron AND/OR its compounds
- Also known as: Desferal, desferoxamine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing